Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). - Wikidata - awgldk - TriplyDB

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

http://www.wikidata.org/entity/Q27852197

about

Persistent androgen receptor addiction in castration-resistant prostate cancer Targeting the adaptive molecular landscape of castration-resistant prostate cancer CIViC database Therapeutic targeting of cancers with loss of PTEN function.A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.The biology of castration-resistant prostate cancer A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.Androgen pathway resistance in prostate cancer and therapeutic implications A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations.Genomic Rearrangements of PTEN in Prostate Cancer.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.Investigational serine/threonine kinase inhibitors against prostate cancer metastases.Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors.Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors.Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.Is it time for everolimus-based combination in castration-resistant prostate cancer?PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer.

P2860

949011a9ef5fa19b91876069b9c6e73da32d2bbe

P248

Q26777163-FC8728CE-6D54-487B-BA9F-11860C95E1A0 Q27022821-4D197BDF-9F5F-4E57-A3BA-92CAA5687F00 Q27612411-2A69C620-CD88-4811-8FB9-464715E3815C Q27852764-02013CBB-55AC-4C2F-B4F5-9C4189EA6C41 Q33652826-0C00A828-02A0-448B-8B6D-026234A04168 Q33924077-F8DD0568-A6CF-4A71-BCCE-8E2FE128F35A Q34520021-F5AE56E8-8A26-4DFF-8063-0AA522CA4AA3 Q35039889-53665418-44B2-49B3-ACE8-106127C3932D Q35567261-12FBE2CE-748F-41D2-863F-6BCABC5CC05A Q35757977-E54045D2-8B97-4590-BF2F-93A5F7A1D3DD Q36200547-C5585D02-D9AC-4B2F-9499-5B3E574F787E Q36416370-3CF98C4F-BCE9-4B52-8DC8-2F700328AEFE Q37214332-64AD99FC-5D1D-4F05-AEA3-A40AAD9C26D2 Q37385372-B2E959FA-7D2C-42E5-80DE-0FF5B089D545 Q37651691-04BB1BDD-3B21-4D89-B7D0-2BC8760D7614 Q37691056-CA31501B-E83B-483F-9B21-280369D81268 Q38142173-BE63DBAA-DE9B-411F-899E-3FED42939835 Q38184622-EB1900ED-D1D3-41D2-9715-A78141579429 Q38188598-326AA0D9-6BAB-4CE8-B2CE-E004F0D6AC7D Q38206682-8D01F432-B991-4EF7-B5E5-93DBDBBA3FE9 Q38242086-8ECEEB30-7D3A-4A85-8D25-059F380F146D Q38797560-83081987-EF4E-4B53-8E17-DC71E3AA9198 Q38806364-EB103F5D-492D-4ED1-83ED-96640E0EA2A8 Q38922287-96C0D7FF-A316-4929-8C99-B2DE700EB9FB Q39021945-58118B31-88BD-4D32-A9B7-DCAB110612D1 Q39207332-7CDBAEF9-E345-45B9-82AB-C458B78C5FD8 Q39733256-AC07DC6B-4A93-465B-AF93-ABAAD78C7CC9 Q40089006-C1BC2F23-8F99-4780-8D67-417B7100C104 Q40880050-A4D30BA7-4E29-4FF3-B10E-32405D82B852 Q40970978-EC1FDD91-7582-4300-927F-3C9410C70F08 Q41835725-D5428A29-9DE2-427C-91D8-E3BEEB520401 Q41865902-C8D310D5-5FD7-4E2C-9955-E9060C2FEE6D Q41906245-0246B33F-48CC-4964-908A-DD2196488286 Q42139770-9D6B023D-3E59-4164-8B10-354560D64AE2 Q42380390-51D2C583-67E5-499A-B5A5-18768FE96786 Q42633783-17D4BB64-02C7-482E-9C97-F756824BAE0A Q46909057-AEFDD539-5752-4FCA-A0CB-D81BA1CA9BB8 Q47406034-53B7CC6D-CE14-4A57-A28C-BBA10B95B29C Q48091118-9F6D4FCD-B33B-4AA7-9624-E58B583777A6 Q50115573-9C16EDA2-5FEC-4155-BE48-74AC84CA93D0

P2860

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

http://www.wikidata.org/entity/Q27852197

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@ast

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@en

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@nl

type

label

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@ast

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@en

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@nl

prefLabel

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@ast

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@en

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@nl

P1433

Q27852197-3F1481AA-9050-4DDE-BAFE-E8BD9D0CE876

P1476

Q27852197-EE7F0538-57F8-49E7-AC52-6CEAF3770279

P2093

Q27852197-01DB68B0-83F5-41C0-BAE7-A95B45F33D80

Q27852197-044A5534-15D3-4158-902E-149D1C142A1C

Q27852197-1B05C1EE-89A9-4C9B-9ECE-37E8312E8A89

Q27852197-25E3ACEF-6774-4733-81ED-695653FD55A5

Q27852197-2B116BB5-3B26-4C2A-BA19-1BF1FAF59646

Q27852197-354E5565-2CA7-404D-B725-6F116FB153BD

Q27852197-49F51F5F-AC4E-49B3-A7C8-BB44AABA1121

Q27852197-4ABF58F9-C8A3-431F-8804-24589B9DC6A6

Q27852197-5C9D73F0-FB63-4D77-ABD9-EFACBEC45282

Q27852197-6037A705-0953-4E43-963E-49E93BF45021

P304

Q27852197-77C2209E-FAB9-4C97-BF4F-898CD06F6A5C

P31

Q27852197-10508564-8853-413F-BFB4-4A75C39845B3

P356

Q27852197-0D83D565-C082-43A9-BD82-DA8AA60F817E

P407

Q27852197-34065FEF-ADFB-4CA5-8317-C101C0AE09A5

P433

Q27852197-51877A57-5FB4-4A0F-B002-5291F1CAA68D

P478

Q27852197-B13262F1-FC12-402C-9FB9-4B3C7EBE52F4

P50

Q27852197-C724BDDD-132E-4A3C-A965-2E08B0BE40DC

P577

Q27852197-0BC06FDA-06CD-4197-A556-613622139AF9

P5875

Q27852197-ABF02A9C-A4E9-49D1-B9B1-C718B37260AD

P698

Q27852197-4E180191-0695-4063-AA36-3085237FA268

P921

Q27852197-4692A31D-D2A3-4093-8CEA-26A1BE81F53C

Q27852197-4AB4C9F4-83F4-4CEE-A347-6C180A09FE50

P356

J.EURURO.2013.03.040

P1433

European Urology

P1476

Phase 2 trial of single-agent ...... prostate cancer (SAKK 08/08).

@en

P2093

Arnoud J Templeton

http://www.w3.org/2001/XMLSchema#string

Beat Müller

http://www.w3.org/2001/XMLSchema#string

Christian Rothermundt

http://www.w3.org/2001/XMLSchema#string

Cornelia Dröge

http://www.w3.org/2001/XMLSchema#string

Daniela Bärtschi

http://www.w3.org/2001/XMLSchema#string

Dirk Klingbiel

http://www.w3.org/2001/XMLSchema#string

Eva Fechter

http://www.w3.org/2001/XMLSchema#string

Frank Stenner

http://www.w3.org/2001/XMLSchema#string

George Thalmann

http://www.w3.org/2001/XMLSchema#string

Jan H Rüschoff

http://www.w3.org/2001/XMLSchema#string

P304

150-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2013.03.040

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Ruedi Aebersold

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237088187

http://www.w3.org/2001/XMLSchema#string

P698

23582881

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial